• 1
    Dzhugashvili M, Pichenot C, Dunant A, et al. Surgical clips assist in the visualization of the lumpectomy cavity in three-dimensional conformal accelerated partial-breast irradiation. Int J Radiat Oncol Biol Phys. 2010; 76: 1320-1324.
  • 2
    Allred DC, Wu Y, Mao S, et al. Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. Clin Cancer Res. 2008; 14: 370-378.
  • 3
    Bijker N, Peterse JL, Duchateau L, et al. Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol. 2001; 19: 2263-2271.
  • 4
    Fisher B, Dignam J, Wolmark N, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol. 1998; 16: 441-452.
  • 5
    Houghton J, George WD, Cuzick J, et al. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet. 2003; 362: 95-102.
  • 6
    Lazovich DA, White E, Thomas DB, Moe RE. Underutilization of breast-conserving surgery and radiation therapy among women with stage I or II breast cancer. JAMA. 1991; 266: 3433-3438.
  • 7
    Kelemen JJ 3rd, Poulton T, Swartz MT, Jatoi I. Surgical treatment of early-stage breast cancer in the Department of Defense Healthcare System. J Am Coll Surg. 2001; 192: 293-297.
  • 8
    Ballard-Barbash R, Potosky AL, Harlan LC, et al. Factors associated with surgical and radiation therapy for early stage breast cancer in older women. J Natl Cancer Inst. 1996; 88: 716-726.
  • 9
    Farrow DC, Hunt WC, Samet JM. Geographic variation in the treatment of localized breast cancer. N Engl J Med. 1992; 326: 1097-1101.
  • 10
    Sariego J. Regional variation in breast cancer treatment throughout the United States. Am J Surg. 2008; 196: 572-574.
  • 11
    Kennedy T, Stewart AK, Bilimoria KY, et al. Treatment trends and factors associated with survival in T1aN0 and T1bN0 breast cancer patients. Ann Surg Oncol. 2007; 14: 2918-2927.
  • 12
    Recht A, van Dongen JA, Fentiman IS, et al. Third meeting of the DCIS Working Party of the EORTC (Fondazione Cini, Isola S. Giorgio, Venezia, 28 February 1994)—conference report. Eur J Cancer. 1994; 30A: 1895-1900.
  • 13
    Silverstein MJ, Lagios MD. Use of predictors of recurrence to plan therapy for DCIS of the breast. Oncology (Williston Park). 1997; 11: 393-406, 409-310; discussion 413-395.
  • 14
    Silverstein MJ, Parker R, Grotting JC, et al. Ductal carcinoma in situ (DCIS) of the breast: diagnostic and therapeutic controversies. J Am Coll Surg. 2001; 192: 196-214.
  • 15
    van de Vijver MJ. Biological variables and prognosis of DCIS. Breast. 2005; 14: 509-519.
  • 16
    Hughes LL, Wang M, Page DL, et al. Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009; 27: 5319-5324.
  • 17
    Keisch M, Vicini F, Beitsch P, et al. American Society of Breast Surgeons MammoSite Radiation Therapy System Registry Trial: ductal carcinoma-in-situ subset analysis—4-year data in 194 treated lesions. Am J Surg. 2009; 198: 505-507.
  • 18
    Keisch M, Vicini F, Kuske RR, et al. Initial clinical experience with the MammoSite breast brachytherapy applicator in women with early-stage breast cancer treated with breast-conserving therapy. Int J Radiat Oncol Biol Phys. 2003; 55: 289-293.
  • 19
    Aberle DR, Allegra CJ, Ganschow P, et al. NIH state-of-the-science conference statement: diagnosis and management of ductal carcinoma in situ (DCIS). NIH Consens State Sci Statements. 2009; 26: 1-27.
  • 20
    Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999; 353: 1993-2000.
  • 21
    Athas WF, Adams-Cameron M, Hunt WC, et al. Travel distance to radiation therapy and receipt of radiotherapy following breast-conserving surgery. J Natl Cancer Inst. 2000; 92: 269-271.
  • 22
    Schroen AT, Brenin DR, Kelly MD, et al. Impact of patient distance to radiation therapy on mastectomy use in early-stage breast cancer patients. J Clin Oncol. 2005; 23: 7074-7080.
  • 23
    McGinnis LS, Menck HR, Eyre HJ, et al. National Cancer Data Base survey of breast cancer management for patients from low income zip codes. Cancer. 2000; 88: 933-945.
  • 24
    Whelan T, Levine M, Gafni A, et al. Mastectomy or lumpectomy? Helping women make informed choices. J Clin Oncol. 1999; 17: 1727-1735.
  • 25
    Allred DC, Clark GM, Molina R, et al. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol. 1992; 23: 974-979.
  • 26
    Allred DC, Clark GM, Tandon AK, et al. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol. 1992; 10: 599-605.
  • 27
    Storm FK, Gilchrist KW, Warner TF, Mahvi DM. Distribution of Hsp-27 and HER-2/neu in in situ and invasive ductal breast carcinomas. Ann Surg Oncol. 1995; 2: 43-48.